On 30 July, Linn Co, LLC (NASDAQ:LNCO) reported Total revenues of approximately $322 million for the second quarter 2015, which includes losses on oil and natural gas derivatives of approximately $191 million; Improved lease operating expenses by 18 percent to approximately $141 million for the second quarter 2015, compared to $173 million for the first quarter 2015.Linn Co, LLC (NASDAQ:LNCO) belongs to Basic Materials sector. Its weekly performance is -50.16%. On last trading day company shares ended up $3.11. Linn Co, LLC (NASDAQ:LNCO) distance from 50-day simple moving average (SMA50) is -64.23%.
Fitbit Inc. (NYSE:FIT) projects profit of seven cents to 10 cents a share on revenue between $335 million and $365 million for the current quarter and earnings of 69 cents to 77 cents a share on sales of $ 1.6 billion to $1.7 billion for the year. Fitbit Inc. (NYSE:FIT) shares increased 3.92% in last trading session and ended the day at $51.64. FIT Gross Margin is 49.50% and its return on assets is 17.30%.
On 30 July, Cambrex Corporation (NYSE:CBM) reported GAAP diluted EPS from continuing operations was $0.60 versus $0.63 in the second quarter last year and Adjusted diluted EPS was $0.63 compared to $0.35 in the same quarter last year.On 05 August, Cambrex Corporation. (NYSE:CBM) shares increased 3.30% and was closed at $53.82. CBM EPS growth in last 5 year was 38.60%. Cambrex Corporation. (NYSE:CBM) year to date (YTD) performance is 148.94%.
Tarena International, Inc. (NASDAQ:TEDU) announced that it will release its unaudited financial results for the second quarter of fiscal year 2015 ended June 30, 2015, after the U.S. markets close on Tuesday, August 18, 2015. Tarena International, Inc. (NASDAQ:TEDU) ended the last trading day at $12.68. Company weekly volatility is calculated as 4.35% and price to cash ratio as 4.41. Tarena International, Inc. (NASDAQ:TEDU) showed a weekly performance of 6.11%.
On 29 July, Cara Therapeutics, Inc. (NASDAQ:CARA) announced the pricing of its underwritten public offering of 3,763,440 shares of its common stock at a public offering price of $18.60 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Cara Therapeutics, are expected to be approximately $70 million. Cara Therapeutics Inc. (NASDAQ:CARA) shares increased 3.62% in last trading session and ended the day at $22.92. CARA return on assets is -31.90%. Cara Therapeutics Inc. (NASDAQ:CARA) quarterly performance is 128.29%.